Hepatic impairment No dose adjustment is necessary in patients with moderate or reasonable (Baby-Pugh A or B) hepatic impairment (see area five.2). Exposure to midostaurin and its active metabolite CGP62221 is substantially decreased in people with extreme hepatic impairment than that in clients with regular hepatic purpose (see portion 5.Present-d… Read More